Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

Gene therapy for neurological, and in particular neurodegenerative, disease is now a reality. A number of early phase clinical trials have been completed and several are currently in progress. In view of this, it is critically important to evaluate the immunological risk associated with neurological gene therapy, which has clear implications for trial safety and efficacy. Moreover, it is imperative in particular to identify factors indicating potential high risk. In the light of recent advances in understanding immune regulation in the central nervous system (CNS) and with the continued development of new gene delivery vectors, this review critically assesses the current knowledge of immunobiology within the CNS in terms of likely immunological risk pertaining to viral vectors and gene therapy applications for neurodegenerative disease.

Original publication

DOI

10.1038/gt.2010.2

Type

Journal article

Journal

Gene Ther

Publication Date

04/2010

Volume

17

Pages

448 - 458

Keywords

Central Nervous System, Gene Silencing, Gene Transfer Techniques, Genetic Therapy, Genetic Vectors, Humans, Immunity, Innate, Models, Biological, Neurodegenerative Diseases